• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

Warfarin (Coumadin®) - Induced Bleeding

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.

Emergency Reversal of Warfarin

Emergency reversal of warfarin ISTH Ravi Sarode, ISTH satellite symposium (video)

Learn more

Kcentra® Phase III Data Published in the Lancet

Study Finds Kcentra® is Superior to Plasma in Patients Needing Warfarin Reversal for Urgent Surgical or Invasive Procedures

Learn more

CMS Extends New Technology Add-On Payment for CSL Behring’s Kcentra®

Designation Helps Improve Patient Access to Kcentra in the Inpatient Hospital Setting

Learn more


Patients who are at risk of serious cardiovascular events due to blood clots from inappropriate coagulation are treated with anticoagulants (e.g. heparin and oral anticoagulants such as warfarin (Coumadin®)).1-2 The development of oral anticoagulants is an active area of pharmacological research and there are molecules that are newly available on the market or entering approval. Examples of these new oral anticoagulants are dabigatran and rivaroxaban. The former is a direct thrombin inhibitor; the latter, a direct FXa inhibitor.3

Heparin, short-acting and injected, enhances the formation of complexes between antithrombin and a number of coagulation factors. It also impairs platelet function.4 The main class of oral anticoagulants is the vitamin K antagonists, which disrupt the production of vitamin K-dependent clotting factors (factors II, VII, IX and X). Warfarin is the most commonly used vitamin K antagonist. Vitamin K antagonists have been used effectively for over 50 years and are primarily indicated for:4

  • Primary and secondary prevention of venous thromboembolism
  • Prevention of stroke, recurrent infarction or death in patients with acute myocardial infarction
  • Prevention of myocardial infarction in men at high risk
  • Prevention of systemic embolism in high-risk patients with mitral stenosis
  • Prevention of thromboembolic complications in patients with atrial fibrillation

CSL Behring Products

Beriplex® P/N (in some areas known as Confidex®) is a CSL Behring product indicated for the treatment and perioperative prophylaxis of bleeding in acquired deficiency of the vitamin K-dependent coagulation factors caused by treatment with oral anticoagulants (e.g. warfarin), or in case of overdose of oral anticoagulants, when rapid correction of the deficiency is required.

In the U.S. Beriplex® P/N has been approved as Kcentra®, and is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or needing an urgent surgery or other invasive procedure.

Package Inserts

Product Websites

Beriplex.co.uk (United Kingdom)
Kcentra.com (United States)

Not all products are available in every country. To learn what products are available in your country, visit your CSL Behring country site.

Last Updated: 4/21/2015 1:45 PM
  • E-mail
  • Print
  • Share